 Mary Bessesen
Concepts (205)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Protective Devices | 6 | 2021 | 13 | 2.650 |
Why?
| | Infection Control | 7 | 2019 | 135 | 1.550 |
Why?
| | Health Personnel | 10 | 2021 | 588 | 1.550 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 5 | 2016 | 190 | 1.480 |
Why?
| | Staphylococcal Infections | 5 | 2016 | 346 | 1.310 |
Why?
| | Respiratory Tract Infections | 5 | 2021 | 331 | 1.230 |
Why?
| | Bacteremia | 5 | 2020 | 161 | 1.140 |
Why?
| | Equipment Reuse | 2 | 2015 | 10 | 1.070 |
Why?
| | Cross Infection | 5 | 2016 | 205 | 1.070 |
Why?
| | Disinfection | 2 | 2015 | 108 | 0.960 |
Why?
| | Masks | 4 | 2021 | 48 | 0.940 |
Why?
| | Carrier State | 3 | 2016 | 57 | 0.800 |
Why?
| | Antimicrobial Stewardship | 1 | 2023 | 95 | 0.790 |
Why?
| | Veterans | 3 | 2020 | 1208 | 0.740 |
Why?
| | Diabetic Foot | 1 | 2020 | 23 | 0.720 |
Why?
| | Rifampin | 1 | 2020 | 69 | 0.700 |
Why?
| | Osteomyelitis | 1 | 2020 | 110 | 0.640 |
Why?
| | Influenza, Human | 5 | 2022 | 554 | 0.620 |
Why?
| | Nose | 2 | 2015 | 58 | 0.620 |
Why?
| | Sepsis | 1 | 2023 | 531 | 0.590 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 174 | 0.540 |
Why?
| | Anti-HIV Agents | 2 | 2018 | 664 | 0.520 |
Why?
| | HIV Infections | 3 | 2018 | 2459 | 0.460 |
Why?
| | Medication Adherence | 1 | 2018 | 556 | 0.450 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 1999 | 113 | 0.420 |
Why?
| | Occupational Exposure | 2 | 2019 | 277 | 0.400 |
Why?
| | Polymers | 1 | 2015 | 482 | 0.400 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 260 | 0.390 |
Why?
| | Catheters, Indwelling | 1 | 2010 | 81 | 0.360 |
Why?
| | Catheter-Related Infections | 1 | 2010 | 60 | 0.360 |
Why?
| | Osteoporosis | 1 | 2012 | 229 | 0.360 |
Why?
| | Delivery of Health Care | 6 | 2022 | 867 | 0.340 |
Why?
| | Catheterization, Central Venous | 1 | 2010 | 95 | 0.340 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 105 | 0.320 |
Why?
| | Microbiota | 1 | 2015 | 656 | 0.320 |
Why?
| | Anti-Bacterial Agents | 5 | 2023 | 1510 | 0.290 |
Why?
| | Influenza Vaccines | 2 | 2022 | 500 | 0.290 |
Why?
| | Humans | 36 | 2023 | 118974 | 0.280 |
Why?
| | Elastomers | 2 | 2015 | 29 | 0.260 |
Why?
| | Mycobacterium avium | 1 | 2004 | 22 | 0.240 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1999 | 224 | 0.240 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2004 | 19 | 0.240 |
Why?
| | Molecular Typing | 1 | 2013 | 18 | 0.240 |
Why?
| | Mycobacterium avium-intracellulare Infection | 2 | 2004 | 62 | 0.230 |
Why?
| | Polymerase Chain Reaction | 3 | 2015 | 1012 | 0.230 |
Why?
| | Peritonitis | 1 | 2004 | 79 | 0.230 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2013 | 63 | 0.230 |
Why?
| | Feasibility Studies | 2 | 2015 | 749 | 0.220 |
Why?
| | Coronavirus OC43, Human | 1 | 2021 | 5 | 0.210 |
Why?
| | Adult | 12 | 2023 | 31512 | 0.210 |
Why?
| | Orthomyxoviridae Infections | 1 | 2022 | 53 | 0.210 |
Why?
| | Male | 16 | 2020 | 57801 | 0.190 |
Why?
| | Escherichia coli | 2 | 2013 | 758 | 0.190 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 140 | 0.190 |
Why?
| | Viruses | 1 | 2021 | 96 | 0.180 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2019 | 20 | 0.180 |
Why?
| | Placebos | 1 | 2020 | 202 | 0.180 |
Why?
| | Attitude | 1 | 2021 | 231 | 0.180 |
Why?
| | Staphylococcus aureus | 2 | 2015 | 394 | 0.170 |
Why?
| | Hepatitis B, Chronic | 1 | 1999 | 18 | 0.170 |
Why?
| | Lamivudine | 1 | 1999 | 59 | 0.170 |
Why?
| | Foot | 1 | 2020 | 106 | 0.170 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 100 | 0.170 |
Why?
| | Financing, Government | 1 | 1999 | 40 | 0.170 |
Why?
| | Middle Aged | 9 | 2020 | 27617 | 0.160 |
Why?
| | Secondary Prevention | 1 | 2020 | 227 | 0.160 |
Why?
| | Mandatory Programs | 1 | 2018 | 16 | 0.160 |
Why?
| | Outpatients | 1 | 2021 | 325 | 0.160 |
Why?
| | Female | 12 | 2020 | 61565 | 0.160 |
Why?
| | Nasal Cavity | 2 | 2016 | 47 | 0.160 |
Why?
| | Sterilization | 1 | 2017 | 12 | 0.150 |
Why?
| | Antibiosis | 1 | 2015 | 7 | 0.140 |
Why?
| | Streptococcus mitis | 1 | 2015 | 8 | 0.140 |
Why?
| | Lactobacillus | 1 | 2015 | 23 | 0.140 |
Why?
| | Vaccination | 3 | 2021 | 1222 | 0.140 |
Why?
| | Retrospective Studies | 6 | 2020 | 12978 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 119 | 0.130 |
Why?
| | Nasal Mucosa | 1 | 2016 | 97 | 0.130 |
Why?
| | Catalase | 1 | 2015 | 123 | 0.130 |
Why?
| | Pyrimethamine | 1 | 1995 | 1 | 0.130 |
Why?
| | Sulfadoxine | 1 | 1995 | 4 | 0.130 |
Why?
| | Double-Blind Method | 1 | 2020 | 1687 | 0.130 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1995 | 25 | 0.130 |
Why?
| | Disease Transmission, Infectious | 1 | 2015 | 56 | 0.130 |
Why?
| | Equipment Contamination | 1 | 2015 | 55 | 0.130 |
Why?
| | Treatment Outcome | 4 | 2020 | 9342 | 0.130 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 755 | 0.130 |
Why?
| | Reference Standards | 1 | 2015 | 176 | 0.130 |
Why?
| | Occupational Diseases | 1 | 2016 | 136 | 0.120 |
Why?
| | Efficiency, Organizational | 2 | 2018 | 126 | 0.120 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 554 | 0.120 |
Why?
| | Risk Factors | 4 | 2021 | 9000 | 0.120 |
Why?
| | Medical Errors | 1 | 2015 | 89 | 0.120 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 164 | 0.120 |
Why?
| | Aged | 3 | 2020 | 19657 | 0.120 |
Why?
| | Virus Diseases | 1 | 2016 | 198 | 0.120 |
Why?
| | Prospective Studies | 3 | 2020 | 6471 | 0.120 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4596 | 0.120 |
Why?
| | HIV-1 | 1 | 1999 | 776 | 0.110 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 514 | 0.110 |
Why?
| | Mycobacterium Infections | 1 | 1993 | 61 | 0.110 |
Why?
| | Cohort Studies | 3 | 2020 | 5116 | 0.110 |
Why?
| | Biomarkers | 1 | 2023 | 3588 | 0.110 |
Why?
| | Prevalence | 2 | 2013 | 2326 | 0.110 |
Why?
| | Bone Density Conservation Agents | 1 | 2012 | 61 | 0.110 |
Why?
| | Osteoporotic Fractures | 1 | 2012 | 51 | 0.100 |
Why?
| | Risk Assessment | 2 | 2016 | 3057 | 0.100 |
Why?
| | United States Department of Veterans Affairs | 1 | 2015 | 555 | 0.100 |
Why?
| | Incidence | 2 | 2019 | 2424 | 0.100 |
Why?
| | Ergonomics | 1 | 2010 | 23 | 0.090 |
Why?
| | Listeria monocytogenes | 1 | 1990 | 110 | 0.090 |
Why?
| | Metagenome | 1 | 2010 | 121 | 0.090 |
Why?
| | United States | 4 | 2018 | 12555 | 0.080 |
Why?
| | Hospitalization | 2 | 2015 | 1785 | 0.080 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6561 | 0.080 |
Why?
| | Molecular Epidemiology | 2 | 2013 | 69 | 0.080 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 965 | 0.070 |
Why?
| | Cytosine | 1 | 2005 | 46 | 0.070 |
Why?
| | Organophosphonates | 1 | 2005 | 94 | 0.060 |
Why?
| | Herpes Simplex | 1 | 2005 | 90 | 0.060 |
Why?
| | Young Adult | 1 | 2020 | 10793 | 0.060 |
Why?
| | Adolescent | 3 | 2020 | 18480 | 0.060 |
Why?
| | Ambulatory Care | 2 | 2019 | 482 | 0.060 |
Why?
| | Immunocompetence | 1 | 2004 | 43 | 0.060 |
Why?
| | Fluoroquinolones | 1 | 2013 | 42 | 0.060 |
Why?
| | beta-Lactams | 1 | 2013 | 28 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 380 | 0.060 |
Why?
| | Inpatients | 2 | 2020 | 388 | 0.050 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2022 | 37 | 0.050 |
Why?
| | Virulence Factors | 1 | 2013 | 140 | 0.050 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2022 | 39 | 0.050 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 170 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2005 | 654 | 0.040 |
Why?
| | Hepatitis B e Antigens | 1 | 1999 | 2 | 0.040 |
Why?
| | Program Evaluation | 2 | 2015 | 845 | 0.040 |
Why?
| | Drug Resistance | 1 | 1999 | 167 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 542 | 0.040 |
Why?
| | Treatment Failure | 1 | 1999 | 341 | 0.040 |
Why?
| | Genotype | 1 | 2013 | 1882 | 0.040 |
Why?
| | Absenteeism | 1 | 2018 | 38 | 0.040 |
Why?
| | Surgical Instruments | 1 | 2017 | 49 | 0.040 |
Why?
| | Hospital Costs | 1 | 2017 | 110 | 0.040 |
Why?
| | Operating Rooms | 1 | 2017 | 90 | 0.040 |
Why?
| | Recurrence | 1 | 1999 | 975 | 0.030 |
Why?
| | Immunization Programs | 1 | 2018 | 206 | 0.030 |
Why?
| | Hand Hygiene | 1 | 2015 | 7 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2004 | 2674 | 0.030 |
Why?
| | Seasons | 1 | 2018 | 461 | 0.030 |
Why?
| | Pentamidine | 1 | 1995 | 3 | 0.030 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 28 | 0.030 |
Why?
| | Personal Protective Equipment | 1 | 2015 | 50 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 333 | 0.030 |
Why?
| | Zidovudine | 1 | 1995 | 77 | 0.030 |
Why?
| | Workplace | 1 | 2016 | 222 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 1995 | 656 | 0.030 |
Why?
| | Occupational Health | 1 | 2015 | 172 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 310 | 0.030 |
Why?
| | Digestive System | 1 | 1991 | 30 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2015 | 405 | 0.030 |
Why?
| | Listeria | 1 | 1990 | 6 | 0.020 |
Why?
| | Patients' Rooms | 1 | 2010 | 13 | 0.020 |
Why?
| | Facility Design and Construction | 1 | 2010 | 12 | 0.020 |
Why?
| | Manikins | 1 | 2010 | 26 | 0.020 |
Why?
| | Time and Motion Studies | 1 | 2010 | 23 | 0.020 |
Why?
| | Diarrhea | 1 | 1991 | 181 | 0.020 |
Why?
| | Hand Disinfection | 1 | 2010 | 22 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 1990 | 182 | 0.020 |
Why?
| | Bacterial Typing Techniques | 1 | 2010 | 43 | 0.020 |
Why?
| | DNA, Ribosomal | 1 | 2010 | 79 | 0.020 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 120 | 0.020 |
Why?
| | Quality Control | 1 | 2010 | 159 | 0.020 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1995 | 334 | 0.020 |
Why?
| | Health | 1 | 2010 | 81 | 0.020 |
Why?
| | Staphylococcus epidermidis | 1 | 2010 | 70 | 0.020 |
Why?
| | Feedback | 1 | 2010 | 153 | 0.020 |
Why?
| | Checklist | 1 | 2010 | 81 | 0.020 |
Why?
| | Workload | 1 | 2010 | 128 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 6412 | 0.020 |
Why?
| | Problem Solving | 1 | 2010 | 145 | 0.020 |
Why?
| | Species Specificity | 1 | 1990 | 565 | 0.020 |
Why?
| | Equipment Design | 1 | 2010 | 519 | 0.020 |
Why?
| | Cues | 1 | 2010 | 297 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 299 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 314 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 143 | 0.020 |
Why?
| | Attention | 1 | 2010 | 408 | 0.020 |
Why?
| | Biodiversity | 1 | 2010 | 378 | 0.020 |
Why?
| | Motivation | 1 | 2010 | 506 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2010 | 635 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1990 | 1795 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 2871 | 0.020 |
Why?
| | Simplexvirus | 1 | 2005 | 86 | 0.020 |
Why?
| | Drug Resistance, Viral | 1 | 2005 | 98 | 0.020 |
Why?
| | Child | 2 | 2021 | 19129 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 244 | 0.020 |
Why?
| | Bacteria | 1 | 1990 | 757 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2513 | 0.010 |
Why?
| | Life Tables | 1 | 1995 | 17 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 267 | 0.010 |
Why?
| | Australia | 1 | 1995 | 212 | 0.010 |
Why?
| | Mycobacterium avium Complex | 1 | 1995 | 93 | 0.010 |
Why?
| | North America | 1 | 1995 | 266 | 0.010 |
Why?
| | Europe | 1 | 1995 | 356 | 0.010 |
Why?
| | Survival Rate | 1 | 1995 | 1720 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1995 | 3171 | 0.000 |
Why?
|
|
Bessesen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|